| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/17/2004 | US6692956 Recombinant adenoviral vectors |
| 02/17/2004 | US6692936 Novel polypeptide belonging to the class of proteins known as g-protein coupled receptors |
| 02/17/2004 | US6692908 Prevention and treatment of HCV infection employing antibodies that inhibit the interaction of HCV virions with their receptor |
| 02/17/2004 | US6692907 Conserved motif of hepatitis C virus E2/NS1 region |
| 02/17/2004 | US6692753 Potentiation of the immune response |
| 02/17/2004 | US6692752 Administering vaccine formulation comprising adjuvant and antigen which is or is derived from herpes simplex virus-1 glycoprotein d, herpes simplex virus-2 glycoprotein d, or immunological fragment thereof |
| 02/17/2004 | US6692751 Methods and systems for producing recombinant viral antigens |
| 02/17/2004 | US6692750 Introducing into cells recombinant alphavirus rna genome and helper rna encoding alphavirus structural proteins, including coding sequences for proteins and cis acting replication signals; incubating to produce infectious virus particles |
| 02/17/2004 | US6692746 Tumor killing effects of enterotoxins, superantigens, and related compounds |
| 02/17/2004 | US6692744 Betaglycan as an inhibin receptor and uses thereof |
| 02/17/2004 | US6692742 Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| 02/17/2004 | US6692741 Treatment of acute lung injury and fibrosis with antagonists of β6-specific antibodies |
| 02/17/2004 | US6692739 Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| 02/17/2004 | CA2112667C Monoclonal antibodies to putative hcv ns5 proteins and methods for using same |
| 02/17/2004 | CA2075288C Anthracycline-conjugates |
| 02/12/2004 | WO2004013631A2 Compositions and methods for diagnosis and therapy of cancer |
| 02/12/2004 | WO2004013629A2 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases |
| 02/12/2004 | WO2004013317A1 A method of obtaining a bacteriophage strain of increased affinity to eukaryotic cells, preparations containing it, and applications of bacteriophages |
| 02/12/2004 | WO2004013311A2 Compositions and methods relating to ovarian specific genes and proteins |
| 02/12/2004 | WO2004013309A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE |
| 02/12/2004 | WO2004013308A2 Maxs as modifiers of the axin pathway and methods of use |
| 02/12/2004 | WO2004013306A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/12/2004 | WO2004013279A2 Helix-hairpin-helix motifs to manipulate properties of dna processing enzymes |
| 02/12/2004 | WO2004013174A1 Use of disease-associated gene |
| 02/12/2004 | WO2004013172A2 Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| 02/12/2004 | WO2004013166A2 S. aureus antigene |
| 02/12/2004 | WO2004013151A2 Campylobacter glycans and glycopeptides |
| 02/12/2004 | WO2004012769A1 Therapeutic inhibitionof protein kinases in cancer cells |
| 02/12/2004 | WO2004012768A1 Tolerance induction with help of a combination of a lfa-1 inhibitor and a costimulation inhibitor and/or a mtor inhibitor |
| 02/12/2004 | WO2004012767A1 Medicinal agent and method for curing erectile dysfunction |
| 02/12/2004 | WO2004012685A2 Shed antigen vaccine with dendritic cells adjuvant |
| 02/12/2004 | WO2004012681A2 Cancer vaccines containing epitopes of oncofetal antigen |
| 02/12/2004 | WO2004012657A2 Beta-glucan containing composites, methods for manufacturing and for using such composites |
| 02/12/2004 | WO2003103570A3 Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles |
| 02/12/2004 | WO2003094963A3 Methylated immunostimulatory oligonucleotides and methods of using the same |
| 02/12/2004 | WO2003094957A3 Methods of therapy for inducing tolerance |
| 02/12/2004 | WO2003093307A8 Mycobacterial antigens and uses thereof |
| 02/12/2004 | WO2003093306A3 Nucleic acids and proteins from streptococcus groups a & b |
| 02/12/2004 | WO2003091414A3 Adipocyte complement related protein zacrp8 |
| 02/12/2004 | WO2003089584A3 Use of parapox b2l protein to modify immune responses to administered antigens |
| 02/12/2004 | WO2003087832A3 Diagnosis of carcinoma using raigi polypeptides |
| 02/12/2004 | WO2003086041A3 Binding agents and their use in targeting tumor cells |
| 02/12/2004 | WO2003076583A3 Genetically engineered phage and the use of genetically engineered phage to deliver nucleic acid to bacteria |
| 02/12/2004 | WO2003072789A3 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors |
| 02/12/2004 | WO2003072012A3 Oral dna composition for hepatitis b virus chronic infection |
| 02/12/2004 | WO2003068923A9 Signal for packaging of influenza virus vectors |
| 02/12/2004 | WO2003060080A3 Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| 02/12/2004 | WO2003054150A3 Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| 02/12/2004 | WO2003050502A3 Prospective identification and characterization of breast cancer stem cells |
| 02/12/2004 | WO2003047684A3 Method for intracellular modifications within living cells using pulsed electric fields |
| 02/12/2004 | WO2003039485A3 Stable liquid pharmaceutical formulation of igg antibodies |
| 02/12/2004 | WO2003039404A3 Methods for treating ocular neovascular diseases |
| 02/12/2004 | WO2003033670A3 Method for preparation of single chain antibodies |
| 02/12/2004 | WO2003033653B1 Affinity enhancement agents |
| 02/12/2004 | WO2003016470A3 Enhancing the efficacy of immunotherapies by supplementing with complement |
| 02/12/2004 | WO2003010282A3 Interleukin-1 beta antibodies |
| 02/12/2004 | WO2002100330A3 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES |
| 02/12/2004 | WO2002090542A8 Antigenic epitopes of factor viii, inhibitors directed against said epitopes and use thereof |
| 02/12/2004 | WO2002077232A3 Compositions and methods relating to breast specific genes and proteins |
| 02/12/2004 | WO2002076507A3 Uses of opg ligand to modulate immune responses |
| 02/12/2004 | WO2002069907A8 Anti-neovasculature preparations for cancer |
| 02/12/2004 | WO2002067863A3 Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions |
| 02/12/2004 | WO2002066647A3 Type 2 ctokine receptor and nucleic acids encoding same |
| 02/12/2004 | WO2002059609A3 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 02/12/2004 | WO2002055702A3 Human proteins, polynucleotides encoding them and methods of using the same |
| 02/12/2004 | WO2002053700A3 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 02/12/2004 | WO2002046411A3 Intestinal proteins |
| 02/12/2004 | WO2002034893A3 Synthetic viruses and uses thereof |
| 02/12/2004 | US20040030118 Methods for regulating hematopoiesis using CpG-oligonucleotides |
| 02/12/2004 | US20040030117 Attenuating mutations and methods of making them, the alphavirus vector delivers the heterologous nucleotide sequence to the cells of the bone, bone marrow, and/or bone-associated connective tissue |
| 02/12/2004 | US20040030106 Novel compounds and process |
| 02/12/2004 | US20040029827 Remedies for heart failure |
| 02/12/2004 | US20040029806 Chlamydia infections; antiarthritic agents; cardiovascular disorders |
| 02/12/2004 | US20040029279 The packaging systems are based on the expression of split-helper functions by coinfecting cells with recombinant vectors, such as recombinant poxvirus vectors |
| 02/12/2004 | US20040029251 Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture |
| 02/12/2004 | US20040029247 Regulation of human adenylate cyclase, type iv |
| 02/12/2004 | US20040029232 Novel G-protein coupled receptors |
| 02/12/2004 | US20040029219 The proteins are antigenic and are useful as vaccine components to raise a protective immune response against Candida |
| 02/12/2004 | US20040029197 Novel human cancer/testis antigen and gene thereof |
| 02/12/2004 | US20040029179 Higher molecular weight entities and uses therefor |
| 02/12/2004 | US20040029174 End selection in directed evolution |
| 02/12/2004 | US20040029150 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/12/2004 | US20040029147 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis |
| 02/12/2004 | US20040029146 Diagnosis and treatment of infectious diseases such as chlamydia |
| 02/12/2004 | US20040029125 Diagnosis, therapy, prevention autoimmune diseases; genetic engineering; culture product; reducing gene expression |
| 02/12/2004 | US20040029118 Computer readable medium having recorded thereon given nucleotide sequence; use in identifying commercially important nucleic acid fragments |
| 02/12/2004 | US20040029106 Duplexed parvovirus vectors |
| 02/12/2004 | US20040028727 Dry formulation for transcutaneous immunization |
| 02/12/2004 | US20040028705 Mutants of clostridium difficile toxin B and methods of use |
| 02/12/2004 | US20040028703 Genetic engineered, low molecular weight drug; therapy, vaccine; extraction of Clostridium |
| 02/12/2004 | US20040028701 E2 subunit vaccine comprising recombinant pestivirus E2 protein |
| 02/12/2004 | US20040028700 Antigenic proteins of shrimp white spot syndrome virus and uses thereof |
| 02/12/2004 | US20040028698 Vaccine |
| 02/12/2004 | US20040028695 Prevent anthrax infections; fusion protein; forming vaccine |
| 02/12/2004 | US20040028693 Fusion protein viricides |
| 02/12/2004 | US20040028692 Sensitization process for antigen-presenting cells and means for implementing the process |
| 02/12/2004 | US20040028690 Nontoxic mucosal adjuvant |
| 02/12/2004 | US20040028688 Vaccine for the prevention of bacterial infection of the bovine mammary gland |
| 02/12/2004 | US20040028685 EphA2 monoclonal antibodies and methods of use thereof |
| 02/12/2004 | US20040028684 Cancer diagnosis and assays for screening anti-cancer agents |